Human iPSC-derived microglia-like cell generation program
exploratoryresearch program · medium · Wed Jan 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Identify transcription factor combinations that rapidly differentiate human iPSCs into specialized microglia-like cells.
Iterative high-throughput single-cell transcription factor screening; six-factor expression of SPI1, CEBPA, FLI1, MEF2C, CEBPB, and IRF8 to generate microglia-like cells from human iPSCs.
Nature Communications publication reported generation of transcriptionally and functionally similar human microglia-like cells within 4 days.
Six transcription factors were sufficient to differentiate human iPSCs into microglia-like cells with transcriptional and functional similarity to primary human microglia within 4 days.
TFome cellular programming platform
preclinicalplatform · high · Thu Feb 08 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Enable scalable development of off-the-shelf iPSC-based cell therapies by programming cell fates for gastrointestinal, neurological, and immunological disease applications.
Plug-and-play cellular programming platform using synthetic biology, gene editing, cell engineering, machine learning, and single-step iPSC differentiation/programming.
GC Therapeutics states it is using TFome to advance potential best-in-class off-the-shelf iPSC-based cell therapy programs.
Gastrointestinal disease iPSC cell therapy programs
undiscloseddrug program · medium
Develop off-the-shelf iPSC-based cell therapies for gastrointestinal diseases.
Cell therapy programs generated through the TFome cellular programming platform using iPSC differentiation/cell engineering methods.
Listed by the company as one of the disease focus areas for advancing potential best-in-class cell therapy programs.
Human iPSC-derived microglia-like cell programming
exploratoryresearch program · medium
Identify transcription factor combinations that rapidly generate specialized human microglia-like cells from iPSCs.
Iterative, high-throughput pooled single-cell transcription factor screening followed by iPSC differentiation using SPI1, CEBPA, FLI1, MEF2C, CEBPB, and IRF8.
A 2025 Nature Communications publication reports validation of a six-transcription-factor combination that differentiates human iPSCs into microglia-like cells within 4 days.
Generated cells showed transcriptional and functional similarity to primary human microglia; the work also described a computational method for exploring single-cell transcription factor perturbation data to infer causal gene regulatory networks.
Immunological disease iPSC cell therapy programs
undiscloseddrug program · medium
Develop off-the-shelf iPSC-based cell therapies for immunological diseases.
Cell therapy programs generated through the TFome cellular programming platform using iPSC differentiation/cell engineering methods.
Listed by the company as one of the disease focus areas for advancing potential best-in-class cell therapy programs.
Neurological disease iPSC cell therapy programs
undiscloseddrug program · medium
Develop off-the-shelf iPSC-based cell therapies for neurological diseases.
Cell therapy programs generated through the TFome cellular programming platform using iPSC differentiation/cell engineering methods.
Listed by the company as one of the disease focus areas for advancing potential best-in-class cell therapy programs.
Off-the-shelf iPSC-based gastrointestinal disease cell therapy programs
preclinicaldrug program · medium
Develop off-the-shelf iPSC-based cell therapies for gastrointestinal diseases.
iPSC-derived cell therapy generated with GC Therapeutics' TFome cellular programming platform.
Company states it is advancing cell therapy programs focused on gastrointestinal diseases, but no specific target, product candidate, or clinical stage is disclosed.
Off-the-shelf iPSC-based immunological disease cell therapy programs
preclinicaldrug program · medium
Develop off-the-shelf iPSC-based cell therapies for immunological diseases.
iPSC-derived cell therapy generated with GC Therapeutics' TFome cellular programming platform.
Company states it is advancing cell therapy programs focused on immunological diseases, but no specific target, product candidate, or clinical stage is disclosed.
Off-the-shelf iPSC-based neurological disease cell therapy programs
preclinicaldrug program · medium
Develop off-the-shelf iPSC-based cell therapies for neurological diseases.
iPSC-derived cell therapy generated with GC Therapeutics' TFome cellular programming platform; related supplied publications describe transcription-factor-based neuronal and microglia-like cell programming from iPSCs.
Company states it is advancing cell therapy programs focused on neurological diseases; supplied 2025 publication reports generation of human iPSC-derived microglia-like cells using six transcription factors within 4 days.
The supplied 2025 microglia-like cell publication reports that SPI1, CEBPA, FLI1, MEF2C, CEBPB, and IRF8 were sufficient to generate cells with transcriptional and functional similarity to primary human microglia within 4 days.
